<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986868</url>
  </required_header>
  <id_info>
    <org_study_id>27850</org_study_id>
    <nct_id>NCT01986868</nct_id>
  </id_info>
  <brief_title>Identification of Adverse Plaque Characteristics by Coronary MR Angiography</brief_title>
  <official_title>Identification of Adverse Plaque Characteristics by Coronary Magnetic Resonance Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine whether coronary magnetic resonance angiography(CMRA)can&#xD;
      identify adverse plaque characteristics (buildup of fat, cholesterol, calcium, and other&#xD;
      substances found in the blood) seen on coronary computed tomography angiography(CCTA) and&#xD;
      evaluate whether there is a relationship between the adverse plaque characteristics and the&#xD;
      presence of coronary artery wall inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study will examine 20 stable patients who have undergone a clinically-indicated&#xD;
      coronary computed tomography angiography (CCTA) for suspected Coronary Artery Disease. They&#xD;
      will be invited to undergo a research coronary Magnetic Resonance Imaging scan with&#xD;
      contrast(CMRA). Based upon the subject's heart rate, a beta blocker may be administered as&#xD;
      its use has been shown to be effective in producing better images as it widens the arteries.&#xD;
&#xD;
      Researchers will use newly developed non-invasive coronary MRA techniques to compare&#xD;
      information shown on the research CMRA with the clinical CCTA. While CCTA has been&#xD;
      demonstrated to be able to provide data on adverse plaque characteristics (APC's), the&#xD;
      ability of CMRA to evaluate these features is not established.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">January 24, 2018</completion_date>
  <primary_completion_date type="Actual">January 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse plaque characteristics present on CMRA</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Coronary MR Angiography (CMRA)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Coronary MR Angiography(CMRA). A gadolinium-based contrast (Optimark or MultiHance) will be administered as well as a beta blocker which will be assigned based upon heart rate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Coronary MR Angiography (CMRA)</intervention_name>
    <description>Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.</description>
    <arm_group_label>Coronary MR Angiography (CMRA)</arm_group_label>
    <other_name>MRI with contrast</other_name>
    <other_name>MultiHance</other_name>
    <other_name>Optimark</other_name>
    <other_name>Gadolinium-based contrast</other_name>
    <other_name>MRA</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MR angiography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Ability to comprehend and sign informed consent&#xD;
&#xD;
          -  Presence of a non-calcified or mixed plaque without high-grade stenosis in the left&#xD;
             main or a proximal coronary artery segment AND at least one APC present in this plaque&#xD;
             by CCTA (defined as LAP with &lt;30 Hounsfield units or PR with ≥10% increase in the&#xD;
             maximal vessel diameter within the plaque as compared to a proximal reference segment&#xD;
             as previously described10).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High-grade stenosis (≥50% stenosis of the left main artery or ≥70% stenosis of another&#xD;
             proximal coronary segment);&#xD;
&#xD;
          -  Coronary artery stent in the segment with the reference plaque&#xD;
&#xD;
          -  Possible pregnancy&#xD;
&#xD;
          -  Glomerular filtration rate &lt;45 ml/min&#xD;
&#xD;
          -  More than 90 days between CCTA and CMRA study&#xD;
&#xD;
          -  Any significant arrhythmia (e.g. atrial fibrillation, frequent ectopy)&#xD;
&#xD;
          -  Significant asthma&#xD;
&#xD;
          -  History of 2nd or 3rd degree heart block&#xD;
&#xD;
          -  Allergy or known intolerance to beta-blockers&#xD;
&#xD;
          -  Use of phosphodiesterase inhibitor (e.g. Viagra) within the last 48 hours&#xD;
&#xD;
          -  Rapid heart rate (heart rate ≥90 beats/minute)&#xD;
&#xD;
          -  Severe aortic stenosis (Aortic valve area &lt;1.0 cm2 or mean gradient &gt;30 mmHg)&#xD;
&#xD;
          -  Systolic blood pressure &lt;100 mmHg&#xD;
&#xD;
          -  Other contraindication to MRI, including metallic implants (valve replacement,&#xD;
             pacemaker, implantable cardiac defibrillator, metallic spine material), intracranial&#xD;
             clips, metallic fragments in eyes, and claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S Berman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel S. Berman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Coronary Magnetic Resonance Angiography</keyword>
  <keyword>CMRA</keyword>
  <keyword>MRI with contrast</keyword>
  <keyword>MultiHance</keyword>
  <keyword>Optimark</keyword>
  <keyword>Gadolinium-based contrast</keyword>
  <keyword>MRA</keyword>
  <keyword>MR angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

